Trial Profile
An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Agalsidase alfa (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Shire
- 05 Jun 2014 New trial record